Hemostasis, also known as hemorrhage prevention, is the process that stops blood from leaking into a blood vessel. Hemostasis happens when a clot develops at the location of the blood vessel injury, repairing it. This report mainly focuses on surgical hemostatic agents market.
The global Surgical Hemostatic Agents market is projected to reach US$ 5746.2 million in 2029, increasing from US$ 3975 million in 2022, with the CAGR of 5.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Surgical Hemostatic Agents market research.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Surgical Hemostatic Agents market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
J&J
Baxter
BD
Gelita
Pfizer
B Braun
CSL Behring
Ferrosan Medical Devices
Advance Medical Solution
Medtronic
Z-Medica
Marine Polymer
Equimedical
CryoLife
Segment by Type
Gelation Hemostats
Combination Hemostats
Others
Segment by Application
Hospitals
Surgical Centers
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Surgical Hemostatic Agents report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Âé¶¹Ô´´ Channel and Customer Analysis
Chapter 8: Âé¶¹Ô´´ Opportunities and Challenges
Chapter 9: Âé¶¹Ô´´ Conclusions
Chapter 10: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Surgical Hemostatic Agents Âé¶¹Ô´´ Overview
1.1 Product Overview and Scope of Surgical Hemostatic Agents
1.2 Surgical Hemostatic Agents Segment by Type
1.2.1 Global Surgical Hemostatic Agents Âé¶¹Ô´´ Value Comparison by Type (2023-2029)
1.2.2 Gelation Hemostats
1.2.3 Combination Hemostats
1.2.4 Others
1.3 Surgical Hemostatic Agents Segment by Application
1.3.1 Global Surgical Hemostatic Agents Âé¶¹Ô´´ Value by Application: (2023-2029)
1.3.2 Hospitals
1.3.3 Surgical Centers
1.3.4 Other
1.4 Global Surgical Hemostatic Agents Âé¶¹Ô´´ Size Estimates and Forecasts
1.4.1 Global Surgical Hemostatic Agents Revenue 2018-2029
1.4.2 Global Surgical Hemostatic Agents Sales 2018-2029
1.4.3 Global Surgical Hemostatic Agents Âé¶¹Ô´´ Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Surgical Hemostatic Agents Âé¶¹Ô´´ Competition by Manufacturers
2.1 Global Surgical Hemostatic Agents Sales Âé¶¹Ô´´ Share by Manufacturers (2018-2023)
2.2 Global Surgical Hemostatic Agents Revenue Âé¶¹Ô´´ Share by Manufacturers (2018-2023)
2.3 Global Surgical Hemostatic Agents Average Price by Manufacturers (2018-2023)
2.4 Global Surgical Hemostatic Agents Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Surgical Hemostatic Agents, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Surgical Hemostatic Agents, Product Type & Application
2.7 Surgical Hemostatic Agents Âé¶¹Ô´´ Competitive Situation and Trends
2.7.1 Surgical Hemostatic Agents Âé¶¹Ô´´ Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Surgical Hemostatic Agents Players Âé¶¹Ô´´ Share by Revenue
2.7.3 Global Surgical Hemostatic Agents Âé¶¹Ô´´ Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Surgical Hemostatic Agents Retrospective Âé¶¹Ô´´ Scenario by Region
3.1 Global Surgical Hemostatic Agents Âé¶¹Ô´´ Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Surgical Hemostatic Agents Global Surgical Hemostatic Agents Sales by Region: 2018-2029
3.2.1 Global Surgical Hemostatic Agents Sales by Region: 2018-2023
3.2.2 Global Surgical Hemostatic Agents Sales by Region: 2024-2029
3.3 Global Surgical Hemostatic Agents Global Surgical Hemostatic Agents Revenue by Region: 2018-2029
3.3.1 Global Surgical Hemostatic Agents Revenue by Region: 2018-2023
3.3.2 Global Surgical Hemostatic Agents Revenue by Region: 2024-2029
3.4 North America Surgical Hemostatic Agents Âé¶¹Ô´´ Facts & Figures by Country
3.4.1 North America Surgical Hemostatic Agents Âé¶¹Ô´´ Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Surgical Hemostatic Agents Sales by Country (2018-2029)
3.4.3 North America Surgical Hemostatic Agents Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Surgical Hemostatic Agents Âé¶¹Ô´´ Facts & Figures by Country
3.5.1 Europe Surgical Hemostatic Agents Âé¶¹Ô´´ Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Surgical Hemostatic Agents Sales by Country (2018-2029)
3.5.3 Europe Surgical Hemostatic Agents Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Surgical Hemostatic Agents Âé¶¹Ô´´ Facts & Figures by Country
3.6.1 Asia Pacific Surgical Hemostatic Agents Âé¶¹Ô´´ Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Surgical Hemostatic Agents Sales by Country (2018-2029)
3.6.3 Asia Pacific Surgical Hemostatic Agents Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Surgical Hemostatic Agents Âé¶¹Ô´´ Facts & Figures by Country
3.7.1 Latin America Surgical Hemostatic Agents Âé¶¹Ô´´ Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Surgical Hemostatic Agents Sales by Country (2018-2029)
3.7.3 Latin America Surgical Hemostatic Agents Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Surgical Hemostatic Agents Âé¶¹Ô´´ Facts & Figures by Country
3.8.1 Middle East and Africa Surgical Hemostatic Agents Âé¶¹Ô´´ Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Surgical Hemostatic Agents Sales by Country (2018-2029)
3.8.3 Middle East and Africa Surgical Hemostatic Agents Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Surgical Hemostatic Agents Sales by Type (2018-2029)
4.1.1 Global Surgical Hemostatic Agents Sales by Type (2018-2023)
4.1.2 Global Surgical Hemostatic Agents Sales by Type (2024-2029)
4.1.3 Global Surgical Hemostatic Agents Sales Âé¶¹Ô´´ Share by Type (2018-2029)
4.2 Global Surgical Hemostatic Agents Revenue by Type (2018-2029)
4.2.1 Global Surgical Hemostatic Agents Revenue by Type (2018-2023)
4.2.2 Global Surgical Hemostatic Agents Revenue by Type (2024-2029)
4.2.3 Global Surgical Hemostatic Agents Revenue Âé¶¹Ô´´ Share by Type (2018-2029)
4.3 Global Surgical Hemostatic Agents Price by Type (2018-2029)
5 Segment by Application
5.1 Global Surgical Hemostatic Agents Sales by Application (2018-2029)
5.1.1 Global Surgical Hemostatic Agents Sales by Application (2018-2023)
5.1.2 Global Surgical Hemostatic Agents Sales by Application (2024-2029)
5.1.3 Global Surgical Hemostatic Agents Sales Âé¶¹Ô´´ Share by Application (2018-2029)
5.2 Global Surgical Hemostatic Agents Revenue by Application (2018-2029)
5.2.1 Global Surgical Hemostatic Agents Revenue by Application (2018-2023)
5.2.2 Global Surgical Hemostatic Agents Revenue by Application (2024-2029)
5.2.3 Global Surgical Hemostatic Agents Revenue Âé¶¹Ô´´ Share by Application (2018-2029)
5.3 Global Surgical Hemostatic Agents Price by Application (2018-2029)
6 Key Companies Profiled
6.1 J&J
6.1.1 J&J Corporation Information
6.1.2 J&J Description and Business Overview
6.1.3 J&J Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2018-2023)
6.1.4 J&J Surgical Hemostatic Agents Product Portfolio
6.1.5 J&J Recent Developments/Updates
6.2 Baxter
6.2.1 Baxter Corporation Information
6.2.2 Baxter Description and Business Overview
6.2.3 Baxter Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Baxter Surgical Hemostatic Agents Product Portfolio
6.2.5 Baxter Recent Developments/Updates
6.3 BD
6.3.1 BD Corporation Information
6.3.2 BD Description and Business Overview
6.3.3 BD Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2018-2023)
6.3.4 BD Surgical Hemostatic Agents Product Portfolio
6.3.5 BD Recent Developments/Updates
6.4 Gelita
6.4.1 Gelita Corporation Information
6.4.2 Gelita Description and Business Overview
6.4.3 Gelita Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Gelita Surgical Hemostatic Agents Product Portfolio
6.4.5 Gelita Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Pfizer Surgical Hemostatic Agents Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 B Braun
6.6.1 B Braun Corporation Information
6.6.2 B Braun Description and Business Overview
6.6.3 B Braun Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2018-2023)
6.6.4 B Braun Surgical Hemostatic Agents Product Portfolio
6.6.5 B Braun Recent Developments/Updates
6.7 CSL Behring
6.6.1 CSL Behring Corporation Information
6.6.2 CSL Behring Description and Business Overview
6.6.3 CSL Behring Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2018-2023)
6.4.4 CSL Behring Surgical Hemostatic Agents Product Portfolio
6.7.5 CSL Behring Recent Developments/Updates
6.8 Ferrosan Medical Devices
6.8.1 Ferrosan Medical Devices Corporation Information
6.8.2 Ferrosan Medical Devices Description and Business Overview
6.8.3 Ferrosan Medical Devices Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Ferrosan Medical Devices Surgical Hemostatic Agents Product Portfolio
6.8.5 Ferrosan Medical Devices Recent Developments/Updates
6.9 Advance Medical Solution
6.9.1 Advance Medical Solution Corporation Information
6.9.2 Advance Medical Solution Description and Business Overview
6.9.3 Advance Medical Solution Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Advance Medical Solution Surgical Hemostatic Agents Product Portfolio
6.9.5 Advance Medical Solution Recent Developments/Updates
6.10 Medtronic
6.10.1 Medtronic Corporation Information
6.10.2 Medtronic Description and Business Overview
6.10.3 Medtronic Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Medtronic Surgical Hemostatic Agents Product Portfolio
6.10.5 Medtronic Recent Developments/Updates
6.11 Z-Medica
6.11.1 Z-Medica Corporation Information
6.11.2 Z-Medica Surgical Hemostatic Agents Description and Business Overview
6.11.3 Z-Medica Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Z-Medica Surgical Hemostatic Agents Product Portfolio
6.11.5 Z-Medica Recent Developments/Updates
6.12 Marine Polymer
6.12.1 Marine Polymer Corporation Information
6.12.2 Marine Polymer Surgical Hemostatic Agents Description and Business Overview
6.12.3 Marine Polymer Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Marine Polymer Surgical Hemostatic Agents Product Portfolio
6.12.5 Marine Polymer Recent Developments/Updates
6.13 Equimedical
6.13.1 Equimedical Corporation Information
6.13.2 Equimedical Surgical Hemostatic Agents Description and Business Overview
6.13.3 Equimedical Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Equimedical Surgical Hemostatic Agents Product Portfolio
6.13.5 Equimedical Recent Developments/Updates
6.14 CryoLife
6.14.1 CryoLife Corporation Information
6.14.2 CryoLife Surgical Hemostatic Agents Description and Business Overview
6.14.3 CryoLife Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2018-2023)
6.14.4 CryoLife Surgical Hemostatic Agents Product Portfolio
6.14.5 CryoLife Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Surgical Hemostatic Agents Industry Chain Analysis
7.2 Surgical Hemostatic Agents Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Surgical Hemostatic Agents Production Mode & Process
7.4 Surgical Hemostatic Agents Sales and Âé¶¹Ô´´ing
7.4.1 Surgical Hemostatic Agents Sales Channels
7.4.2 Surgical Hemostatic Agents Distributors
7.5 Surgical Hemostatic Agents Customers
8 Surgical Hemostatic Agents Âé¶¹Ô´´ Dynamics
8.1 Surgical Hemostatic Agents Industry Trends
8.2 Surgical Hemostatic Agents Âé¶¹Ô´´ Drivers
8.3 Surgical Hemostatic Agents Âé¶¹Ô´´ Challenges
8.4 Surgical Hemostatic Agents Âé¶¹Ô´´ Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Âé¶¹Ô´´ Size Estimation
10.1.3 Âé¶¹Ô´´ Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
J&J
Baxter
BD
Gelita
Pfizer
B Braun
CSL Behring
Ferrosan Medical Devices
Advance Medical Solution
Medtronic
Z-Medica
Marine Polymer
Equimedical
CryoLife
Ìý
Ìý
*If Applicable.